Lisa Demeter

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group
    L M Demeter
    University of Rochester School of Medicine and Dentistry, NY, USA
    J Virol Methods 75:93-104. 1998
  2. ncbi request reprint HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388
    Lisa M Demeter
    Infectious Diseases Unit, University of Rochester, Rochester, New York 14642, USA
    Clin Infect Dis 39:552-8. 2004
  3. pmc Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience
    Lisa M Demeter
    University of Rochester, Rochester, New York 14642, USA
    HIV Clin Trials 9:11-25. 2008
  4. pmc The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients
    Lisa M Demeter
    Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    HIV Clin Trials 9:61-72. 2008
  5. pmc A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients
    Lisa M Demeter
    University of Rochester School of Medicine and Dentistry, New York, USA
    AIDS 23:357-68. 2009
  6. pmc Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter
    Lisa M Demeter
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Clin Microbiol 40:2089-94. 2002
  7. ncbi request reprint International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations
    L Demeter
    Division of Infectious Diseases, University of Rochester Medical Center, Rochester, New York, USA
    J Acquir Immune Defic Syndr 26:S3-9. 2001
  8. pmc Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
    L M Demeter
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Antimicrob Agents Chemother 44:794-7. 2000
  9. ncbi request reprint A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir
    Scott M Hammer
    Columbia University, New York, NY, USA
    Antivir Ther 8:507-18. 2003
  10. ncbi request reprint Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine
    Carrie Dykes
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Infect Dis 189:1091-6. 2004

Research Grants

Detail Information

Publications35

  1. ncbi request reprint Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group
    L M Demeter
    University of Rochester School of Medicine and Dentistry, NY, USA
    J Virol Methods 75:93-104. 1998
    ....
  2. ncbi request reprint HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388
    Lisa M Demeter
    Infectious Diseases Unit, University of Rochester, Rochester, New York 14642, USA
    Clin Infect Dis 39:552-8. 2004
    ..Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen...
  3. pmc Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience
    Lisa M Demeter
    University of Rochester, Rochester, New York 14642, USA
    HIV Clin Trials 9:11-25. 2008
    ..EFV+IDV plus abacavir (ABC) in 283 nucleoside-experienced HIV-infected patients...
  4. pmc The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients
    Lisa M Demeter
    Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    HIV Clin Trials 9:61-72. 2008
    ....
  5. pmc A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients
    Lisa M Demeter
    University of Rochester School of Medicine and Dentistry, New York, USA
    AIDS 23:357-68. 2009
    ..NIQs < or = 1 may predict poor outcome and identify patients who could benefit from dose escalation...
  6. pmc Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter
    Lisa M Demeter
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Clin Microbiol 40:2089-94. 2002
    ..The delay in the time required for HIV cultures to turn positive should be considered when attempting to obtain an HIV isolate from patients with suppression of plasma viral load...
  7. ncbi request reprint International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations
    L Demeter
    Division of Infectious Diseases, University of Rochester Medical Center, Rochester, New York, USA
    J Acquir Immune Defic Syndr 26:S3-9. 2001
    ..This article describes the experience to date establishing the efficacy, accuracy, reproducibility, and limitations of the phenotypic and genotypic resistance assays used today...
  8. pmc Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
    L M Demeter
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Antimicrob Agents Chemother 44:794-7. 2000
    ..P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates...
  9. ncbi request reprint A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir
    Scott M Hammer
    Columbia University, New York, NY, USA
    Antivir Ther 8:507-18. 2003
  10. ncbi request reprint Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine
    Carrie Dykes
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Infect Dis 189:1091-6. 2004
    ..Selection for indinavir-resistant variants on treatment with indinavir, lamivudine, and zidovudine may occur slowly, depending on the genetic context in which they arise...
  11. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  12. ncbi request reprint Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors
    Robert A Domaoal
    Department of Medicine, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    Int J Biochem Cell Biol 36:1735-51. 2004
    ..The studies summarized in this review provide important insights into potentially useful approaches to minimize the development of HIV-1 resistant to non-nucleoside inhibitors...
  13. pmc Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial
    Robin DiFrancesco
    Department of Pharmacy Practice, SUNY at Buffalo, Buffalo, NY, USA
    Ther Drug Monit 32:458-66. 2010
    ..The application of some of these findings may also be relevant to single-center studies or clinical TDM programs within a hospital...
  14. pmc Sequences in the U3 region of human immunodeficiency virus 1 improve efficiency of minus strand transfer in infected cells
    Dorota Piekna-Przybylska
    Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 712, Rochester, NY 14642, USA
    Virology 410:368-74. 2011
    ..Alteration of segment 1 had the greatest effect. Alteration of motif 9 or both sequences also caused a reduction, but smaller than alteration of segment 1 alone...
  15. pmc Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays
    Carrie Dykes
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Clin Microbiol 48:4035-43. 2010
    ..We propose that discordant results in the MCA and SCA are due to alterations in late events in the virus life cycle that are not captured in an SCA, such as burst size, cell-to-cell transmission, or infected-cell life span...
  16. ncbi request reprint Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection
    Christine E Koval
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Infect Dis 35:491-3. 2002
    ..carinii DNA. We hypothesize that this patient's clinical presentation denotes immune reconstitution syndrome in response to residual P. carinii antigen in the lung...
  17. pmc Clinical significance of human immunodeficiency virus type 1 replication fitness
    Carrie Dykes
    Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Microbiol Rev 20:550-78. 2007
    ..In addition, the strength of the correlations between fitness and clinical outcomes is modest, suggesting that, at present, it would be difficult to utilize these assays for clinical management...
  18. ncbi request reprint Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York
    Amneris E Luque
    Department of Medicine, Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    J Infect Dis 194:428-34. 2006
    ..These observations have implications for the design of future HPV vaccines...
  19. ncbi request reprint Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V
    Christine E Koval
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Virology 353:184-92. 2006
    ..These studies have important implications for the design of more durable NNRTI-nucleoside combination regimens...
  20. pmc Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    J Virol 80:2380-9. 2006
    ..A user-friendly computational tool also has been developed and is publicly available on the World Wide Web at http://www.urmc.rochester.edu/bstools/vfitness/virusfitness.htm...
  21. pmc Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions
    Jiong Wang
    Department of Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
    J Virol 84:9377-89. 2010
    ..For the other NNRTI mutants, reductions in RT content decreased both polymerization and RNase H activity in virions. RNase H reduction was compounded by intrinsic RNase H defects in the mutant RTs...
  22. ncbi request reprint HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies
    Robert A Domaoal
    Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Acquir Immune Defic Syndr 42:405-11. 2006
    ....
  23. pmc vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments
    Jingming Ma
    Department of Biostatistics and Computational Biology, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA
    BMC Bioinformatics 11:261. 2010
    ..The accurate estimation of viral fitness relies on complicated computations based on statistical methods. This calls for tools that are easy to access and intuitive to use for various experiments of viral fitness...
  24. doi request reprint Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments
    Hongyu Miao
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 630, Rochester, NY, 14642, USA
    Bull Math Biol 70:1749-71. 2008
    ..Practical identifiability was investigated via Monte Carlo simulations...
  25. ncbi request reprint HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses
    Jennifer E Snyder-Cappione
    David H Smith Center for Vaccine Biology and Immunology, and Department of Microbiology and Immunology, University of Rochester Medical Center, NY 14642, USA
    J Immunol 176:2662-8. 2006
    ..Analysis of the frequency of directly cytotoxic HIV-specific T cells may be of considerable value in the assessment of disease progression and the potential efficacy of HIV vaccines...
  26. ncbi request reprint Identification of a preferred region for recombination and mutation in HIV-1 gag
    Carrie Dykes
    Department of Medicine, University of Rochester School of Medicine and Dentistry, NY, USA
    Virology 326:262-79. 2004
    ....
  27. pmc Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture
    Carrie Dykes
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Clin Microbiol 44:1930-43. 2006
    ..This flow cytometry-based growth competition assay offers advantages over current assays for HIV replication efficiency and should prove useful for the evaluation of patient samples in clinical trials...
  28. pmc Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference
    Hongyu Miao
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 630, Rochester, New York 14642, USA
    Biometrics 65:292-300. 2009
    ..We expect that the proposed modeling and inference approaches for the DE models can be widely used for a variety of biomedical studies...
  29. pmc Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load
    J Brooks Jackson
    Johns Hopkins Medical Institutions, Carnegie Building, Room 415, 600 North Wolfe St, Baltimore, MD 21287, USA
    J Clin Microbiol 42:2774-6. 2004
    ..0146). Median numbers of copies per milliliter were similar for 112 samples with 50 to 3,000 copies/ml with no difference in sensitivity with a 200-copy/ml cutoff...
  30. ncbi request reprint Drug resistance mutations in HIV-1
    Victoria A Johnson
    Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
    Top HIV Med 11:215-21. 2003
    ..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included...
  31. ncbi request reprint Update of the drug resistance mutations in HIV-1: 2004
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 12:119-24. 2004
  32. ncbi request reprint Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel
    Martin S Hirsch
    Top HIV Med 11:150-4. 2003
    ..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing...
  33. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
    ..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation...
  34. ncbi request reprint Drug resistance mutations in HIV-1
    RICHARD T D'AQUILA
    Vanderbilt University Medical Center, Nashville, TN, USA
    Top HIV Med 11:92-6. 2003
  35. ncbi request reprint Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
    Margaret A Fischl
    AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
    AIDS 21:325-33. 2007
    ..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens...

Research Grants12

  1. Impact of NNRTI-resistance on RNase H & HIV replication
    Lisa Demeter; Fiscal Year: 2007
    ....
  2. Clinical Significance of HIV Replication Fitness
    Lisa Demeter; Fiscal Year: 2007
    ..If these studies are successful, they could identify tests that could help predict clinical outcomes for HIV-infected patients. ..
  3. Impact of NNRTI Resistance on RNase H & HIV Replication
    Lisa Demeter; Fiscal Year: 2005
    ....
  4. DLV RESISTANCE MUTATIONS IN HIV REPLICATIONS
    Lisa Demeter; Fiscal Year: 2000
    ....